You don’t need to know, according to our broken regulatory system When in the lifecycle of a cancer drug should an improvement in survival or quality of life be demonstrated? Some people argue that t...

Fewer than a third of indications approved with immature survival data showed a statistically significant overall survival benefit after approval. Notable inconsistencies in timing and availability of information after approval across different sources emphasise the need for better reporting standards.

The addition of disulfiram to a combination regimen of cisplatin and vinorelbine was well tolerated and appeared to prolong survival in patients with newly diagnosed non-small cell lung cancer. The re...